FJ
Jornayvaz, François
Affiliation entities
Research groups
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Autoimmunity in MASLD : Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptors | European journal of clinical investigation | 2025 | 66 | 111 | |||
| Prise en charge de la dyslipidémie diabétique | Revue médicale suisse | 2025 | 4 | 0 | |||
| Autoantibodies against apolipoprotein A-1 and cadmium : possible links tocardiovascular and liver diseases across multiple models | ESC (European Society of Cardiology) Congress 2025 | 2025 | 5 | 0 | |||
| Autoantibodies against apolipoprotein A-1 and cadmium : Possible links tocardiovascular and liver diseases across multiple models | 93rd EAS (European Atherosclerosis Society) Congress | 2025 | 4 | 0 | |||
| Analogues du GLP-1 dans le traitement du diabète de type 2 et de l’obésité : la panacée ? | Revue médicale suisse | 2025 | 5 | 0 | |||
| Multi-omics correlates of insulin resistance and circadian parameters mapped directly from human serum | EJN. European journal of neuroscience | 2024 | 76 | 129 | |||
| Alterations of lipid homeostasis in morbid obese patients are partly reversed by bariatric surgery | iScience | 2024 | 82 | 52 | |||
| S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects | Science advances | 2024 | 330 | 136 | |||
| Linking antibody against apolipoprotein A-1 to nonalcoholic steatohepatitis in mice | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 4 | 0 | |||
| Corticosteroid therapy in older adults with cancer : Expert recommendations from a task force of the International Society of Geriatric Oncology | Journal of geriatric oncology | 2024 | 34 | 0 | |||
| Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associatedsteatohepatitis in mice | ESC (Europan Society of Cardiology) Congress 2024 | 2024 | 2 | 0 | |||
| Geospatial clustering of auto-antibodies against apolipoprotein A-1, heavy metals,cardiovascular and liver diseases in the general population | ESC (Europan Society of Cardiology) Congress 2024 | 2024 | 5 | 0 | |||
| Diabétologie : ce qui a changé en 2023 | Revue médicale suisse | 2024 | 102 | 5 | |||
| Lysophosphatidylinositols Are Upregulated After Human β-Cell Loss and Potentiate Insulin Release | Diabetes | 2024 | 363 | 3 | |||
| N ADPH oxidases in healthy white adipose tissue and in obesity : function, regulation, and clinical implications | Obesity | 2024 | 103 | 72 | |||
| Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice | International journal of molecular sciences | 2024 | 118 | 93 | |||
| Gastroparésie diabétique et diabète de type 1 | Revue médicale suisse | 2024 | 117 | 2 | |||
| Langerhans Cell Histiocytosis of the Suprasellar Region : Diagnosis on Thyroid Cytology | European thyroid journal | 2024 | 115 | 128 | |||
| Geospatial clustering of auto-antibodies against apolipoprotein A-1, heavy metals, cardiovascular and liver diseases in the general population | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 6 | 0 | |||
| Gynécologie-obstétrique. Prise en charge et dépistage du diabète gestationnel : ce qui a changé en 2023 | Revue médicale suisse | 2024 | 204 | 2 | |||
| Toutes nos différences… | Revue médicale suisse | 2024 | 62 | 2 | |||
| Interprofessional diabetes and foot management in low-and middle-income countries or humanitarian crises contexts | International Diabetes Federation (IDF) virtual congress | 2023 | 55 | 77 | |||
| Pied diabétique : une prise en charge complexe et multidisciplinaire | Revue médicale suisse | 2023 | 125 | 17 | |||
| Nonalcoholic fatty liver disease in type 1 diabetes : where are we? | Polskie Archiwum Medycyny Wewnętrznej | 2023 | 88 | 55 | |||
| GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes | Diabetes & metabolism | 2023 | 130 | 355 | |||
| A global research priority agenda to advance public health responses to fatty liver disease | Journal of hepatology | 2023 | 119 | 225 | |||
| Diabétologie : ce qui a changé en 2022 | Revue médicale suisse | 2023 | 131 | 9 | |||
| Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease | International journal of molecular sciences | 2023 | 125 | 82 | |||
| Circadian organization of lipid landscape is perturbed in type 2 diabetic patients | Cell reports. Medicine | 2023 | 265 | 135 | |||
| Stéatopathie non alcoolique (NAFLD) et diabète : le mauvais mariage | Revue médicale suisse | 2023 | 126 | 26 | |||
| Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testing | European thyroid journal | 2023 | 209 | 200 | |||
| Traitement du diabète de type 2 : et si nous revenions à l’essentiel ? | Revue médicale suisse | 2023 | 91 | 9 | |||
| A multi–society Delphi consensus statement on new fatty liver disease nomenclature | Journal of hepatology | 2023 | 129 | 490 | |||
| The impact of transsphenoidal surgery on pituitary function in patients with non-functioning macroadenomas | Endocrine | 2023 | 135 | 163 | |||
| Neuropathie diabétique : mise au point | Revue Médicale Suisse | 2022 | 162 | 628 | |||
| Effectiveness of Therapeutic Patient Education Interventions in Obesity and Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Nutrients | 2022 | 185 | 202 | |||
| NAFLD: From Mechanisms to Therapeutic Approaches | Biomedicines | 2022 | 149 | 168 | |||
| Allergie à l’insuline : comment faire ? | Revue médicale suisse | 2022 | 137 | 190 | |||
| Non-alcoholic fatty liver disease in type 1 diabetes: prevalence and pathophysiology | Frontiers in endocrinology | 2022 | 154 | 250 | |||
| Diabète pancréatoprive | Revue médicale suisse | 2022 | 533 | 147 | |||
| Pheochromocytoma presented by Takotsubo, unmasked by accumulation of paroxetine, in a cytochrome poor metabolizer patient: A case report | Thérapie | 2022 | 365 | 1 | |||
| Interleukin-18 in metabolism: from mice physiology to human diseases | Frontiers in endocrinology | 2022 | 180 | 244 | |||
| Canakinumab in patients with COVID-19 and type 2 diabetes – a multicentre, randomised, double-blind, placebo-controlled trial | EClinicalMedicine | 2022 | 129 | 96 | |||
| Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity | Endocrine connections | 2022 | 229 | 145 | |||
| (650) Efficacy of therapeutic patient education interventions in metabolic disorders: a systematic review and meta-analysis | 58th EASD Annual Meeting of the European Association for the Study of Diabetes | 2022 | 245 | 7 | |||
| Circulating 1,5-anhydroglucitol as a biomarker of ß-cell mass independent of a diabetes phenotype in human subjects | Journal of clinical endocrinology & metabolism | 2022 | 412 | 2 | |||
| Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days | Annals of surgery | 2022 | 250 | 338 | |||
| NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook | Antioxidants | 2022 | 276 | 338 | |||
| Dernières recommandations européennes sur les dyslipidémies | Revue médicale suisse | 2022 | 379 | 647 | |||
| Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesis | Nature communications | 2022 | 375 | 100 | |||
| Diabète : la pandémie comme révélateur de nos succès/nos failles | Revue médicale suisse | 2022 | 52 | 21 | |||
| Diabétologie | Revue médicale suisse | 2022 | 90 | 57 | |||
| Hépatopathie et diabète de type 2 | Leading Opinions. Médecine Interne | 2022 | 118 | 0 | |||
| Tratamiento podológico del pie diabético | Encyclopédie médico-chirurgicale. Podología | 2022 | 114 | 0 | |||
| Systematic Review and Meta-Analysis of the Usefulness of Epicardial Fat Thickness as a Non-Invasive Marker of the Presence and Severity of Nonalcoholic Fatty Liver Disease | Biomedicines | 2022 | 153 | 111 | |||
| Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes | Cardiovascular diabetology | 2022 | 111 | 272 | |||
| Prise en charge podologique du pied diabétique | Encyclopédie médico-chirurgicale. Podologie | 2022 | 139 | 0 | |||
| Growth differentiation factor-15 prevents glucotoxicity and connexin-36 downregulation in pancreatic beta-cells | Molecular and cellular endocrinology | 2022 | 103 | 131 | |||
| Le diabète : une pandémie oubliée ? | Revue médicale suisse | 2021 | 123 | 236 | |||
| Inhibiteurs du SGLT2 : que des bénéfices? | Revue médicale suisse | 2021 | 377 | 250 | |||
| Is routine measurement of the serum C-reactive protein level helpful during antibiotic therapy for diabetic foot infection? | Diabetes, Obesity and Metabolism | 2021 | 188 | 0 | |||
| Diabète de type MODY : une entité souvent méconnue | Revue médicale suisse | 2021 | 177 | 133 | |||
| Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients | Acta Physiologica | 2021 | 397 | 3 | |||
| Diabétologie | Revue médicale suisse | 2021 | 203 | 2 | |||
| Pathophysiology of NASH in endocrine diseases | Endocrine Connections | 2021 | 220 | 168 | |||
| Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD | International journal of molecular sciences | 2021 | 153 | 187 | |||
| Diabétologie | Revue médicale suisse | 2020 | 242 | 2 | |||
| Diabète: et si on se mettait à la place du patient? | Revue médicale suisse | 2020 | 245 | 0 | |||
| Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting | Diabetes, Obesity and Metabolism | 2020 | 486 | 326 | |||
| Thirteen-year trends in the prevalence of diabetes according to socioeconomic condition and cardiovascular risk factors in a swiss population | BMJ Open Diabetes Res Care | 2020 | 336 | 162 | |||
| Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland | Diabetes, Metabolic Syndrome and Obesity | 2020 | 300 | 177 | |||
| La NASH: une complication moins connue mais importante du diabète | Revue médicale suisse | 2020 | 356 | 0 | |||
| The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet | Translational Research | 2020 | 557 | 288 | |||
| Quelle place pour les inhibiteurs de la DPP-4 en 2020? | Revue médicale suisse | 2020 | 547 | 0 | |||
| Ulcère du pied chez un patient avec un diabète : quelle prise en charge médico-chirurgicale ? | Revue médicale suisse | 2020 | 331 | 1 | |||
| Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case report | BMC Endocrine Disorders | 2020 | 206 | 128 | |||
| Diabète après transplantation rénale : mise au point | Revue médicale suisse | 2020 | 352 | 4 | |||
| Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial | Clinical Infectious Diseases | 2020 | 344 | 779 | |||
| Insuffisance rénale chronique et nouveaux traitements antidiabétiques : tour d'horizon en 2019 | Revue médicale suisse | 2019 | 674 | 274 | |||
| Thirteen-year trends in the prevalence of diabetes in an urban region of Switzerland: a population-based study | Diabetic Medicine | 2019 | 262 | 0 | |||
| Salivary cortisol is not associated with incident insulin resistance or type 2 diabetes mellitus | Endocrine Connections | 2019 | 317 | 109 | |||
| Faut-il prescrire plus d'inhibiteurs SGLT-2 ? | Revue médicale suisse | 2019 | 302 | 133 | |||
| [News in diabetology 2018] | Revue médicale suisse | 2019 | 273 | 84 | |||
| Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism | Scientific Reports | 2019 | 468 | 127 | |||
| Nonalcoholic fatty liver disease burden | Swiss Medical Weekly | 2019 | 312 | 175 | |||
| Prise en charge de la dyslipidémie chez les patients avec un diabète de type 1 | Revue médicale suisse | 2018 | 515 | 48 | |||
| Diabétologie | Revue médicale suisse | 2018 | 416 | 52 | |||
| Observance thérapeutique et empilage médicamenteux | Revue médicale suisse | 2018 | 367 | 171 | |||
| Fibroblast Growth Factor 15/19 - From Basic Functions to Therapeutic Perspectives | Endocrine Reviews | 2018 | 497 | 162 | |||
| Transition optimale hôpital-domicile d'un patient diabétique de type 2 : quelques outils | Revue médicale suisse | 2018 | 563 | 137 | |||
| Consequences of the Adoption of the IADPSG versus Carpenter and Coustan Criteria to Diagnose Gestational Diabetes: A Before-After Comparison | Experimental and Clinical Endocrinology and Diabetes | 2018 | 513 | 2 | |||
| An Overview on Diabetic Foot Infections, including Issues Related to Associated Pain, Hyperglycemia and Limb Ischemia | Current Pharmaceutical Design | 2018 | 488 | 1 | |||
| Diabète prégestationnel : une entité de plus en plus fréquente | Revue médicale suisse | 2018 | 506 | 167 | |||
| Diabète de type 1, activité physique et nouvelles technologies | Revue médicale suisse | 2018 | 766 | 364 | |||
| β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue | JCI insight | 2017 | 583 | 277 | |||
| Utilité de la mesure en continu de la glycémie chez les patients diabétiques de type 2 | Revue médicale suisse | 2017 | 389 | 0 | |||
| Treatment challenges in type 1 diabetes after roux-en-Y gastric bypass | Swiss Medical Weekly | 2017 | 410 | 200 | |||
| AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient mice | Molecular Metabolism | 2017 | 414 | 0 | |||
| Diabète sucré secondaire à une endocrinopathie : quand y penser ? | Revue médicale suisse | 2017 | 547 | 987 | |||
| Diètes cétogènes : la solution miracle ? | Revue médicale suisse | 2017 | 1,333 | 635 | |||
| Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies | Nutrients | 2017 | 467 | 0 | |||
| Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease | Nutrients | 2017 | 489 | 0 | |||
| Traitement du diabète: quand faire appel au diabétologue? | Revue médicale suisse | 2017 | 369 | 193 | |||
| Grip strength is not associated with incident type 2 diabetes mellitus in healthy adults: The CoLaus study | Diabetes Research and Clinical Practice | 2017 | 471 | 0 | |||
| Diabétologie | Revue médicale suisse | 2017 | 406 | 105 | |||
| GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on bone | Molecular Nutrition and Food Research | 2017 | 562 | 394 | |||
| Effects of Antidiabetic Drugs on Gut Microbiota Composition | Genes | 2017 | 440 | 0 | |||
| Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid | Dermatology | 2017 | 425 | 0 | |||
| Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples | Journal of Immunological Methods | 2017 | 397 | 1 | |||
| Place des nouveaux antidiabétiques dans la population gériatrique | Revue médicale suisse | 2016 | 417 | 1 | |||
| Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance | FASEB Journal | 2016 | 369 | 0 | |||
| Fasting glycaemia to simplify screening for gestational diabetes | BJOG: an International Journal of Obstetrics and Gynaecology | 2016 | 591 | 1 | |||
| Diabète gestationnel – quelles sont les approches non médicales ? | Revue médicale suisse | 2016 | 420 | 1 | |||
| Comment faire pour prévenir le diabète de type 2 en Suisse? | Revue médicale suisse | 2016 | 419 | 2 | |||
| Leptin as a Potential Regulator of FGF21 | Cellular physiology and biochemistry | 2016 | 626 | 231 | |||
| Preserving of Postnatal Leptin Signaling in Obesity-Resistant Lou/C Rats following a Perinatal High-Fat Diet | PloS one | 2016 | 518 | 199 | |||
| Sécurité cardiovasculaire des antidiabétiques | Revue médicale suisse | 2016 | 427 | 0 | |||
| Diabétologie | Revue médicale suisse | 2016 | 373 | 0 | |||
| Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection | Arteriosclerosis, Thrombosis, and Vascular Biology | 2016 | 615 | 1 | |||
| Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study | Cardiovascular Diabetology | 2016 | 535 | 220 | |||
| Endocrine causes of nonalcoholic fatty liver disease | World Journal of Gastroenterology | 2015 | 480 | 0 | |||
| Free Fatty Acids Impair FGF21 Action in HepG2 Cells | Cellular physiology and biochemistry | 2015 | 559 | 330 | |||
| Metformine : nouvelles données pour une ancienne molécule | Revue médicale suisse | 2015 | 443 | 2 | |||
| Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21 | Journal of Endocrinology | 2015 | 818 | 381 | |||
| Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? | Molecular and Cellular Endocrinology | 2015 | 539 | 1,551 | |||
| Classification du diabète : vers une hétérogénéité croissante | Revue médicale suisse | 2015 | 394 | 0 | |||
| Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue | PloS one | 2015 | 622 | 308 | |||
| Le diabète en 2015 : en augmentation constante, mais avec une offre thérapeutique qui s'élargit | Revue médicale suisse | 2015 | 403 | 1 | |||
| Prise en charge des facteurs de risque des maladies cardiovasculaires : qu'est-ce qui a vraiment changé en 15 ans ? | Revue médicale suisse | 2015 | 426 | 1 | |||
| Edulcorants artificiels et diabète : faux amis ? | Revue médicale suisse | 2015 | 396 | 0 | |||
| ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content | Journal of Lipid Research | 2015 | 468 | 0 | |||
| Serum Vitamin D Concentrations Are Not Associated with Insulin Resistance in Swiss Adults | The Journal of nutrition | 2015 | 539 | 0 | |||
| Transition en diabétologie | Revue médicale suisse | 2015 | 558 | 1 | |||
| Diets and nonalcoholic fatty liver disease: The good and the bad | Clinical nutrition | 2014 | 673 | 1 | |||
| Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 Diabetes | Journal of general internal medicine | 2014 | 590 | 1 | |||
| Maladies hépatiques chroniques et diabète | Revue médicale suisse | 2014 | 489 | 0 | |||
| Traitement combiné d'insuline et d'analogue du GLP-1 : qu'en attendre ? | Revue médicale suisse | 2014 | 573 | 0 | |||
| Ostα-/- mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivity | American Journal of Physiology. Gastrointestinal and Liver Physiology | 2014 | 455 | 0 | |||
| Muscle-specific activation of Ca(2+)/calmodulin-dependent protein kinase IV increases whole-body insulin action in mice | Diabetologia | 2014 | 502 | 0 | |||
| Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice | Endocrinology | 2013 | 759 | 0 | |||
| CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance | Proceedings of the National Academy of Sciences | 2013 | 502 | 0 | |||
| Increased FGF21 plasma levels in humans with sepsis and SIRS | Endocrine connections | 2013 | 626 | 263 | |||
| Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside | Diabetes & metabolism | 2013 | 633 | 0 | |||
| Enhanced fasting glucose turnover in mice with disrupted action of TUG protein in skeletal muscle | Journal of Biological Chemistry | 2013 | 504 | 0 | |||
| Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance | Endocrinology | 2013 | 462 | 0 | |||
| Sport et diabète de type 1 | Revue médicale suisse | 2013 | 668 | 0 | |||
| Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance | Journal of Endocrinology | 2013 | 671 | 0 | |||
| Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance | Endocrinology | 2012 | 459 | 0 | |||
| Development of insulin resistance in mice lacking PGC-1α in adipose tissues | Proceedings of the National Academy of Sciences | 2012 | 417 | 0 | |||
| Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice | Journal of Biological Chemistry | 2012 | 436 | 0 | |||
| Sommeil et diabète | Revue médicale suisse | 2012 | 508 | 0 | |||
| Diabète et stéatose hépatique non alcoolique | Revue médicale suisse | 2012 | 626 | 0 | |||
| Weight and mortality in adults with diabetes | JAMA | 2012 | 593 | 0 | |||
| Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients | Acta Diabetologica | 2012 | 436 | 0 | |||
| Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice | Cell Metabolism | 2011 | 455 | 0 | |||
| Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance | Hepatology | 2011 | 445 | 1 | |||
| Pregnancy does not accelerate corticotroph tumor progression in Nelson's syndrome | Journal of Clinical Endocrinology and Metabolism | 2011 | 477 | 0 | |||
| SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function | Diabetes | 2011 | 397 | 0 | |||
| Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2 | Proceedings of the National Academy of Sciences | 2011 | 501 | 0 | |||
| Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance | Cell Metabolism | 2010 | 467 | 0 | |||
| A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain | American Journal of Physiology. Endocrinology and Metabolism | 2010 | 443 | 0 | |||
| Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals | Diabetologia | 2010 | 639 | 0 | |||
| Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients | NMCD. Nutrition Metabolism and Cardiovascular Diseases | 2009 | 639 | 0 | |||
| Mucocutaneous papillomatous papules in Cowden's syndrome | Clinical and experimental dermatology | 2008 | 550 | 0 | |||
| Assessment of hepatic glucose metabolism by indirect calorimetry in combination with a non-invasive technique using naturally enriched 13C glucose in healthy children and adolescents | Hormone Research | 2004 | 427 | 0 | |||
| Metabolism of oral glucose in children born small for gestational age: evidence for an impaired whole body glucose oxidation | Metabolism | 2004 | 433 | 0 | |||
| Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1 | The Journal of clinical endocrinology and metabolism | 2003 | 637 | 0 |
